(HealthDay News) -- A drug derived from shark cartilage failed to improve survival in patients with advanced lung cancer, researchers report.
The disappointing results, which came in the final stage of testing, showed that the drug didn't help extend the life spans of patients with inoperable stage III non-small cell lung cancer.
Scientists have been testing drugs derived from shark cartilage because it appears to prevent blood vessels from growing around tumors. The hope is that the drugs will prevent cancer cells from being fed by blood, which allows them to grow.
Researchers led by Dr. Charles Lu, of the University of Texas M.D. Anderson Cancer Center, tested the specific drug in question, known as AE-941, on patients in the United States and Canada. Read more...
Joint Mender for Joint Care
No comments:
Post a Comment